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Abstract
Gastric cancer is a multifactorial neoplastic pathology 
numbering among its causes both environmental and 
genetic predisposing factors. It is mainly diffused in 
South America and South-East Asia, where it shows 
the highest morbility percentages and it is relatively 
scarcely diffused in Western countries and North Amer-
ica. Although molecular mechanisms leading to gastric 
cancer development are only partially known, three 
main causes are well characterized: Helicobacter pylori  
(H. pylori ) infection, diet rich in salted and/or smoked 
food and red meat, and epithelial cadherin (E-cadherin ) 
mutations. Unhealthy diet and H. pylori  infection are 
able to induce in stomach cancer cells genotypic and 
phenotypic transformation, but their effects may be 
crossed by a diet rich in vegetables and fresh fruits. 
Various authors have recently focused their attention 
on the importance of a well balanced diet, suggesting 
a necessary dietary education starting from childhood. 
A constant surveillance will be necessary in people car-
rying E-cadherin  mutations, since they are highly prone 
in developing gastric cancer, also within the inner 
stomach layers. Above all in the United States, several 
carriers decided to undergo a gastrectomy, preferring 
changing their lifestyle than living with the awareness 
of the development of a possible gastric cancer. This 
kind of choice is strictly personal, hence a decision 
cannot be suggested within the clinical management. 
Here we summarize the key points of gastric cancer 
prevention analyzing possible strategies referred to the 
different predisposing factors. We will discuss about 
the effects of diet, H. pylori  infection and E-cadherin  
mutations and how each of them can be handled.
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INTRODUCTION
Gastric carcinoma is one of  the most frequent cancers 
and it can be considered one of  the major contributors 
to mortality worldwide[1]. Environmental and genetic 
causes may be involved and a pivotal role in reducing 
the incidence of  gastric carcinoma may be addressed to 
prevention. Diet rich in salted and smoked food, so as 
Helicobacter pylori (H. pylori) infection, are the best known 
environmental causes[2-6], whereas epithelial cadherin (E-
cadherin) and runt-related transcription factor 3 (RUNX3) 
loss of  expression are often genetic trademarks of  gas-
tric cancer[7-11]. Hence, prevention might be considered 
from different viewpoints. A general improvement of  
lifestyle, including a diet rich in vegetables and a reduced 
intake of  red meat and of  alcohol[12] may be helpful in 
preventing gastric cancer, yet more specific strategy have 
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to be adopted according to different people environ-
mental and genetic background. In some cases, such as 
in families carrying E-cadherin mutations, prevention may 
be focused above all on well scheduled endoscopies and, 
sometimes, preventive gastrectomy may be the most 
suitable choice[13,14].
H. pylori infection and unhealthy diet cause epigen-
etic and genetic modification, respectively, in stomach 
cells. In fact, higher methylation levels were found both 
in some marker CpG islands[15] and in promoter regions 
of  microRNA genes[16,17] in patients suffering from 
H. pylori infection. On the other hand, high N-nitroso 
compounds were found in case of  diet rich in red meat, 
whereas polycyclic aromatic hydrocarbons and hetero-
cyclic amines are typical of  high intake of  smoked and 
roasted food. All these compounds are highly mutagenic, 
hence their introduction through nutrition represents 
an important predisposing factor to stomach cells car-
cinogenic transformation. Mechanisms by which high 
consumption of  salted food contribute to gastric cancer 
development have been not completely clarified so far, 
yet a synergic action with H. pylori and N-nitroso com-
pounds[18-20] and an increase in inflammatory response of  
gastric epithelium were found[21].
Prevention of  gastric cancer has to be performed act-
ing on two different directions: removing and contrast-
ing possible causes. Considering diet habits, a powerful 
strategy is represented by replacing processed with fresh 
food, taking care of  introducing high intake of  vegeta-
bles. Adopting a healthy diet is an effective approach to 
prevent stomach tumors in people suffering or not, from 
H. pylori infection. Yet, in this last case a suitable eradica-
tion therapy has to be established and a well scheduled 
follow-up has to performed. Here we will discuss in de-
tail all these different sides, together with the prevention 
strategy of  gastric cancer caused by E-cadherin mutations.
PReveNTION Of gasTRIC CaNCeR IN 
PeOPle sUffeRINg fROm H. PYLORI 
INfeCTION
H. pylori is a gram-negative bacterium colonizing stom-
ach which may cause gastritis in infected patients. It is 
able to survive in gastric acidic environment because of  
its capability of  synthesizing urease, an enzyme which 
can neutralize the stomach acidic pH[22]. Various papers 
focused their attention on the pivotal role exerted by cy-
totoxic associated genes in the pathogenicity island (Cag 
PAI), vacuolating toxin A and IceA (induced by contact 
with epithelium A), whose positivity characterizes differ-
ent H. pylori strains, in clinical response of  patients[23-25]. 
More specifically, their data show that in genesis of  
gastric cancer a key role may be exerted by Cag PAI[26-28], 
a group of  about 30 genes encoded by a 40 kilobases 
region. Among the thirty related proteins, some of  them 
are involved in the constitution of  type Ⅳ secretion 
system (T4SS) a “molecular syringe”[22,29] helping CagA 
(a protein belonging to the Cag PAI group) to enter into 
gastric cells cytosol. CagA has been considered the most 
important virulence factor involved in gastric cancer 
development mediated by H. pylori[30-32], although in a 
recent paper Rizzato et al[33] highlighted other important 
genes, such as CagE and CagL, whose polymorphisms 
may affect patients clinical outcome. H. pylori seems to 
exert a role in mechanisms leading to gastric cancer by 
inducing methylation in different genes[33], interfering 
with apoptotic pathways[34] and by causing inflammatory 
events leading to gastritis, then to atrophic gastritis and 
possibly to gastric cancer[35-38]. The infection is generally 
treated by triple therapy, based on proton pump inhib-
itor-clarithromycin-amoxicillin or metronidazole treat-
ment[39], yet this strategy recently produced disappointing 
results[40-43]. A possible explanation was referred to an 
increase of  H. pylori strains showing clarithromycin re-
sistance[40,44-46] which challenged different studies focused 
on different therapeutic protocols. These are based on 
drugs administrations deferred over time, the so called 
sequential 10-d therapy[47-49], on the concomitant four 
drugs administration[50], or on both[51]. 
In spite of  the increased successes and improve-
ments of  therapies to eradicate H. pylori, controversial 
data[6,52,53] are referred to similar successful decrease of  
gastric cancer due to eradication itself. Most of  papers 
discussing this paradox show by consent that a key role 
may be referred to the step of  the gastric disease de-
velopment in which eradication therapy is performed. 
So, an early eradication therapy, during young age, is 
more effective in preventing gastric cancer, rather than 
a therapy performed in elder age, when phenotypic and 
genotypic transformations induced by H. pylori are more 
serious[54-57]. Then, prevention of  gastric cancer in people 
affected by H. pylori may be performed starting by an 
early diagnosis followed by an early eradication therapy. 
Recent papers describe new forms of  gastric cancer 
developing after H. pylori eradication therapy. Yamamoto 
et al[58] focused their attention on phenotypic and geno-
typic differences gastric cancers arising in patients under-
gone to the therapy and patients not undergone, but suf-
fering from the infection. Matsuo et al[59], instead, studied 
patients undergone to eradication therapy, patients not 
undergone and patients negative for H. pylori infection. 
Results gained by the two groups showed discrepancy 
about histotype of  gastric cancers arisen in patients treat-
ed to eradicate H. pylori, since Yamamoto et al[58] found 
prevalence of  diffuse histotype, while Matsuo et al[59] 
found prevalence of  intestinal histotype. These differ-
ences suggest the need of  considering a higher number 
of  patients, but these studies highlight the possibility 
of  developing gastric carcinoma also after eradication 
therapy. 
H. pylori is a powerful carcinogen, belonging to group 
1, according to the International Agency for Research 
on Cancer[60], since it is able to induce genetic changes, 
such as hypermethylation events[34,61], contributing to cell 
transformation[62]. Hence, a support strategy in preven-
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tion H. pylori carcinogenic potential may be focused in 
reducing its infective potential. A significant contribu-
tion may derive from food. Broccoli sulforaphane exerts 
protective effects in case of  H. pylori infection, since it 
can induce phase 2 detoxication enzymes, such as gluta-
thione-S-transferase (GST), and may act as a bactericide 
in gastric rodents tissue[63]. These data may be referred 
to humans too, as it was shown that H. pylori eradica-
tion induces restored GST levels and considering that 
GST decreased levels are an hallmark gastric cancer, also 
led by H. pylori infection[64]. Moreover, C57BL/6 female 
mice infected with H. pylori Sydney strain 1, and whose 
diet was maintained in a high salt intake, when fed with 
broccoli rich in sulforaphane showed reduced stomach 
bacterial colonization, a reduced level of  tumour ne-
crosis factor-alpha and interleukin-1 beta[65]. In humans 
consuming 70g/d of  broccoli rich in sulforaphane, a 
reduced level of  urease (biomarker of  H. pylori inflam-
mation) in breath test and of  serum pepsinogen Ⅰ and 
Ⅱ (both inflammation biomarkers)[66] was found. Then, 
it can be deduced that the highest sulforaphane intake, 
the lowest H. pylori inflammation levels.
Considering the plethora of  publications focused on 
H. pylori carcinogenic potential it can be gathered that its 
mutagenic effects must be stopped as more promptly, 
as possible. This goal may be achieved with an early 
diagnosis, an early eradication and a healthy diet rich in 
cruciferous crops.
Since most of  H. pylori infections are asymptomat-
ic[67], screening programs may be useful, especially among 
children, so as to reduce the possibility of  accumulating 
mutations from childhood. It has to be stated that H. 
pylori infection in children is above all diffuse in develop-
ing countries, because of  poor socioeconomic status, as 
showed from various authors[68-70]. Moreover it is also re-
sponsible of  worsening their malnutrition, since H. pylori 
reduces the absorption of  various micronutrients[70-72], 
and then of  contributing to their growth failure[72-74]. 
Hence, an effective strategy of  early diagnosis and treat-
ment would be desirable, so as to combining short-term 
and long term advantages, against malnutrition/growth 
failure and possible gastric cancer, respectively. Yet, ex-
tensive population screening programs would represent 
a welfare spending disproportionately high with respect 
to actual advantages, so as to encourage focused screen-
ing just on really high risk groups such as Japanese[75]. 
Obviously, this restriction of  screening programs would 
be more targeted to prevention of  gastric cancer than of  
malnutrition, which may be caused by H. pylori. Various 
non invasive tests helping H. pylori diagnosis in children 
are available, such as [13C] urea breath test and stool 
antigen test[68] and different periods of  administration of  
triple therapy showed a good efficacy in treating the in-
fection[76,77]. Notwithstanding, close attention should be 
paid to the use of  multiple antibacterial therapies during 
childhood, because of  the possibility of  H. pylori clar-
ithromycine resistant strains development[68,78]. Hence, a 
good strategy to have a balance between the possibility 
of  preventing and fighting against H. pylori and the ne-
cessity to bypass antibiotics resistance of  some strains, 
may be represented by an healthy diet rich in cruciferous 
crops. Their intake starting from childhood may contrast 
possible infections, contributing to decrease infective po-
tential of  H. pylori. Then, good healthy habits acquired in 
young age may be helpful from beginning of  their gain-
ing and lifelong. A regular intake of  cruciferous crops 
could help to impair both immediate and long term ef-
fects of  H. pylori infection, reducing the consequent mal-
nutrition and the possible accumulation of  DNA modi-
fications. Diet rich in cruciferous and, more generically, 
in vegetables, is a pivotal element of  a healthy lifestyle (as 
it will be discussed in the next paragraph), hence it can 
be adopted from the early childhood, without a particu-
lar starting age. 
A special topic is represented by the influence of  H. 
pylori infection on aetiogenesis of  Barrett’s esophagus, 
a pathology consisting in the substitution of  the nor-
mal squamous epithelium of  the distal esophagus with 
columnar epithelium[79]. This condition predisposes to 
esophageal adenocarcinoma, since the characterizing 
columnar epithelium looks like a partial intestinal meta-
plasia, defined specialized intestinal metaplasia[79]. Gas-
troesophageal reflux is a well known cause of  Barrett’s 
esophagus, since an excess of  acidic fluid accumulating 
in cardia after meals, can induce modifications of  the 
squamous mucosa lining[80]. Therapy of  this condition 
is based on the use of  proton pump inhibitors, so as 
to control gastric fluid pH. The capability of  H. pylori 
in neutralizing acidic pH of  gastric environment[22] has 
been considered a possible explanation of  the docu-
mented inverse correlation between H. pylori infection 
and Barrett’s esophagus[81]. Yet, in a more recent paper, 
some authors showed that this correlation is tightly relat-
ed to parameters used to perform the comparison. More 
specifically, if  control samples are represented by endo-
scopic reports, H. pylori infection and Barrett’s esopha-
gus are inversely correlated, while if  control samples 
are based on blood donors a clear association cannot be 
found[82]. Since both the papers cited represent a meta 
analysis, their results can be considered an effective over-
view on scientific literature focused on the topic under 
consideration. A concise conclusion cannot be gained, 
since further investigations should be performed and a 
clear mechanism explaining the relationship between H. 
pylori and Barrett’s esophagus is not known[79].
PReveNTION Of gasTRIC CaNCeR 
INDUCeD by DIeT
Stomach is one of  the first organ contacting food, after 
oral mucosa and esophagus, performing the second step 
of  chemical and mechanical digestion. The link between 
food and gastric cancer development has been largely 
studied. Various authors reported that reliable causes 
of  stomach neoplasms are high intake of  red meat[83-85], 
salted[20,86,87] and smoked food[88-90]. These diet habits are 
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source of  compounds with high carcinogenic potential 
such as N-nitroso compounds, polycyclic aromatic hy-
drocarbons and heterocyclic amines. In countries with 
high incidence of  gastric cancer, placed in South-East 
Asia, Maldives and South West America[91] typical dishes 
include fish and vegetables consumption, both fresh and 
salted, fermented and pickled. In 1990, Tsugane et al[92] 
published their results highlighting that Japan popula-
tions living in Hawaii showed a lower incidence rate of  
gastric cancer, if  compared to Japanese resident in Sao 
Paulo, Brazil[92]. Brazilian diet habits include food with 
high N-nitrosation potential such as grilled red meat 
and fish, crustaceans and fried vegetables seasoned with 
large amount of  salt. Other studies focused on the link 
between gastric cancer and salt intake analyzed salt ex-
cretion in 24 h-urine samples of  subjects up to 75 years 
of  age and it was found an almost linear correlation 
between the cumulative mortality rate for gastric cancer 
in five different area of  Japan[93,94]. Moreover, Okinawa, 
the Japanese prefecture with the lowest mortality rate for 
gastric cancer, has diet habits including the lowest salt 
intake of  the whole Japan[93,94]. Hence, the association 
between stomach tumours and salted food was con-
firmed by different ecological and epidemiological stud-
ies, but details of  biological mechanisms involved have 
not been well clarified. An important role seems to be 
exerted if  contemporaneous H. pylori infection occurs. In 
2007, Loh et al[18] published an interesting paper in which 
they showed that high dietary salt intake may enhance 
CagA capability of  moving toward gastric epithelium, 
potentiating H. pylori infection and, hence, transform-
ing power. Previous experiments on H. pylori infected 
Mongolian gerbils showed that high levels of  salt intake 
caused hypergastrinemia[95,96]. Others found that an in-
creased gastrin secretion may contribute to epithelial cell 
growth with concurrent H. pylori infection[97,98]. Finally it 
was found that salt can determine alterations in gastric 
mucus viscosity, allowing N-nitroso compounds to bet-
ter perform their mutation effects[21]. Hence, an effective 
prevention against gastric cancer development may be 
represented by low intake of  salted food, avoiding to 
introduce a compound not mutagenic per se, but whose 
interaction with other predisposing factors may contrib-
ute significantly to the neoplastic pathology. 
High alcohol consumption and cigarette smoking 
may also be considered risk factors related to stomach 
tumours[1,98-100], although some contrasting data were 
published[101,102]. It can be inferred that since alcohol is 
able to induce chronic gastritis, and cigarette smoking 
contribute to absorb mutagenic compounds, both of  
them might be removed in a generally healthy lifestyle. 
Yet, it has to be specified that just high intake of  alcohol 
showed a direct correlation with increased risk of  gastric 
cancer, while it was not found in case of  low, or mod-
erate intake[98]. Preventive effects of  a healthy lifestyle, 
with moderate physical activity, reduced intake of  alco-
hol, fats, red meat and salted food are well established. 
But strategy of  prevention has to include consumption 
of  fresh fruits and vegetables, which seem to exert a 
protective role on gastric cancer development. Different 
authors focused their attention on tomatoes, broccoli, 
citrus fruit and pomegranate because of  their antioxi-
dant, cytostatic and anti-inflammatory properties[103-105]. 
Tomatoes intake decreases micronucleated polychro-
matic erythrocytes and lipid peroxidation, and enhances 
antioxidant status in Swiss mice treated by N-methyl-N’
-nitro-N-nitrosoguanidine (MNNG)[106]. Micronucleated 
polychromic erythrocytes are a direct index of  chromo-
somal damage, whereas final product of  lipids peroxi-
dation may be mutagenic and carcinogenic[107]. Hence, 
tomatoes intake showed a contrasting effect on some of  
the most carcinogenic compounds, namely MNNG. Be-
sides, combination of  lycopene, a carotenoid abundant 
in tomatoes, and S-allylcysteine, an organosulphur which 
can be found in garlic, is able to modulate the apoptosis 
pathway Bcl2-Bax-Bim, so as to reduce carcinogenic 
potential of  MNNG and sodium chloride in stomach of  
Wistar rats[106]. Then it can be gathered that diet habits 
including tomatoes may help in prevention of  gastric 
cancer development, because they can both decrease 
the overall levels of  carcinogens and stimulate apoptotic 
pathways in gastric cancer cells. 
Citrus fruits seem to perform a high level prevention 
because of  their capability of  inhibiting gastric endog-
enous N-nitrosation[108,109] and epidemiological studies 
corroborate this hypothesis[92,108-110]. The mechanism 
through which they exert this inhibition is still investi-
gated, but it was supposed that they can be effective in 
blocking both acid-catalysed nitrosation (ACN), typical 
of  high risk areas, and by biologically catalysed nitrosa-
tion (BCN)[109]. ACN occurs when intragastric environ-
ment has an acidic pH, whereas BCN occurs in nearly 
neutral pH[111], so N-nitrosation phenomenon shows 
independence from stomach pH, but a close relationship 
to quality of  food intake. Yet, the preventive role of  cit-
rus fruits is not only limited to reduce this phenomenon, 
but also to induce G2/M cell cycle arrest in AGS gas-
tric cancer cell line[112], to suppress CD74, an adhesion 
molecule of  urease H. pylori, and to disrupt the related 
ERK1/2 activation pathway in NCI-N87 gastric cancer 
cell line[113,114]. Induction of  apoptosis through caspase-3 
activation was found too[115].
It is noteworthy to mention a paper published in 2004 
describing an epidemiological investigation on Japanese 
males in which it was shown that chronic atrophic gastri-
tis, often first step of  gastric neoplastic transformation, 
was more frequent in men consuming broccoli once or 
more weekly, if  compared to those who ate broccoli less 
frequently[116]. The same authors considered surprising 
the data obtained. They supposed that a more accurate 
diagnostic method for chronic atrophic gastritis, than 
serological determination of  pepsinogen Ⅰ and Ⅱ they 
used, and that a more accurate evaluation of  amount of  
broccoli eaten would have to be performed, since they 
took account just of  tines/weekly consumed, rather than 
precise amount. Moreover a study published in 2008 
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did not show a significant protective role from fruit 
and vegetable intake on gastric cancer development[117]. 
Yet, this study was performed in United States, where a 
generally well nourished population live. This comment 
was recently done also by Key in a recently published re-
view[118], in which the author discussed the effective pro-
tective role of  fresh fruit and vegetables on cancer de-
velopment. He focused his attention on the importance 
of  having at least a moderate intake of  fresh fruits and 
vegetables, but also to pay attention to avoid overweight, 
high salted food and high alcohol consumption.
Contrasting papers on the usefulness of  fresh fruits 
and vegetables intake in preventing gastric cancer, has 
not to be considered an advice of  ignore consumption 
of  this kind of  food. Rather, experimental evidences 
suggesting that different compounds in fruits and veg-
etables may activate apoptotic and cytostatic pathways 
and inhibiting H. pylori adhesion, would have to encour-
age to change unhealthy lifestyle toward healthier habits.
PReveNTION Of gasTRIC CaNCeR IN 
famIlIes CaRRyINg E-CADHERIN 
mUTaTIONs
E-cadherin, also known as Cadherin type 1 (CDH1), is a cell-
adhesion glycoprotein characterized for the first time in 
human cell lines by Shimoyama et al[119]. Its role in gastric 
cancer development was firstly defined by Guilford et al[8], 
who identified a G→T nucleotide substitution in the 
donor splice consensus sequence of  exon 7 in a Maori 
kindred. This mutation produced a truncated protein 
whose final result was a reduced E-cadherin production. 
The family examined showed an early onset of  gastric 
cancer characterized by diffuse histotype, as the other 
two families described who carried a frameshift muta-
tion in exon 15 and a premature stop codon in exon 13, 
respectively. Successively, other authors identified other 
E-cadherin mutations in various worldwide families[120-123]. 
All these germline mutations are dominantly inherited, 
originating the so called Hereditary Diffuse Gastric Can-
cer (HDGC), a dominantly familial cancer syndrome. 
Updated criteria established by the International Gastric 
Cancer Linkage Consortium define that the syndrome of  
HDGC must be characterized by histological confirma-
tion of  diffuse gastric criteria only for one family mem-
ber, inclusion of  individuals with diffuse gastric cancer 
before the age of  40 years without a family history and 
inclusion of  individuals and families with diagnoses of  
both diffuse gastric cancer (including one before the age 
of  50 years) and lobular breast cancer[124]. People belong-
ing to families showing also just one of  these features 
should undergo to genetic test to investigate on possible 
CDH1 mutations. Although among familial gastric cases 
only 1%-3% are carriers of  mutations in CDH1, positive 
results should be followed by well scheduled endoscopic 
surveillance so as to monitor the very first neoplastic le-
sions. Yet, the efficacy of  this strategy may be invalidated 
in cases of  small, or intramucosal, foci[125-127]. In scien-
tific literature total gastrectomy is often performed as a 
prophylactic strategy and, as much often, it represents a 
therapeutic strategy[124-126], just because of  frequent small 
foci undetectable by endoscopical techniques.
The knowledge of  the effects exerted by inherited 
CDH1 mutations, raises different ethical questions. De-
scendants of  carrier families have often to choose if  
undergoing to preventive gastrectomy, or not. Some of  
them preferred right this option, while other did not. In 
both cases physicians have to show possible advantages 
and disadvantages deriving from each choice. The adop-
tion of  a healthy diet, in these cases, although advisable, 
is not sufficient to exert an active and effective preven-
tion of  gastric cancer, since CDH1 loss of  expression 
and/or function represent an important step towards 
carcinogenesis. Hence, people belonging to carrier fami-
lies would have to join a constant endoscopic surveil-
lance with a medical support, to plan the most suitable 
prevention strategy.
CONClUsION
Up to date gastric cancer is one of  the most lethal tu-
mour, especially in South America and South-East Asia, 
where it shows the highest frequency and morbility. Rare 
cases of  HDGC are caused by CDH1 mutations and 
their prevention is above all based on continuous surveil-
lance, generally following an actual mutational diagnosis. 
Non hereditary gastric cancer number among their pre-
disposing factors both H. pylori infection, and unhealthy 
diet including high intake of  salted and smoked food, 
red meat and alcohol and a reduced intake of  vegetables 
and fresh fruit. Various studies have shown molecular 
bases related to preventive effects exerted by a healthy 
diet. More specifically it has been found that crucifer-
ous crops helps to inhibit H. pylori infection and then its 
mutational power. On the other hand, tomatoes, garlic 
and citrus fruits are able to reduce N-nitrosation and to 
induce apoptosis and cell cycle arrest in G2/M phase, re-
spectively. Hence, high consumption of  vegetables helps 
to prevent and to block phenomena triggered both by 
salted and smoked food and red meat, and by H. pylori 
infection. 
Future perspectives related to gastric cancer pre-
vention are, above all, focused on improving strategy 
against H. pylori and discovering molecular mechanisms 
on which healthy diet may exert a function. Very recent 
papers highlight the possibility of  alternative target to 
manage the bacterial infection[128] and to the different 
parameters to determine a really nutrient and balanced 
diet[129]. Again recently, a review written by Nagini[130] 
show an effective summary of  all these last keypoints, 
giving useful hints for further research directions.
RefeReNCes
1 Asombang AW, Kelly P. Gastric cancer in Africa: what do 
we know about incidence and risk factors? Trans R Soc Trop 
Med Hyg 2012; 106: 69-74
132 September 10, 2012|Volume 3|Issue 9|WJCO|www.wjgnet.com
Giordano A et al . Gastric cancer prevention
2 Dikshit RP, Mathur G, Mhatre S, Yeole BB. Epidemiological 
review of gastric cancer in India. Indian J Med Paediatr Oncol 
2011; 32: 3-11
3 Hu J, La Vecchia C, Morrison H, Negri E, Mery L. Salt, pro-
cessed meat and the risk of cancer. Eur J Cancer Prev 2011; 
20: 132-139
4 Dungal N, Sigurjonsson J. Gastric cancer and diet. A pilot 
study on dietary habits in two districts differing markedly 
in respect of mortality from gastric cancer. Br J Cancer 1967; 
21: 270-276 
5 Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chaya-
ma K. Low prevalence of Helicobacter pylori-negative gas-
tric cancer among Japanese. Helicobacter 2011; 16: 415-419 
6 González CA, Agudo A. Carcinogenesis, prevention and 
early detection of gastric cancer: where we are and where 
we should go. Int J Cancer 2012; 130: 745-753 
7 Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, 
Birchmeier W, Sugimura T, Hirohashi S. E-cadherin gene 
mutations in human gastric carcinoma cell lines. Proc Natl 
Acad Sci USA 1994; 91: 1858-1862
8 Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, 
Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cad-
herin germline mutations in familial gastric cancer. Nature 
1998; 392: 402-405
9 Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang 
GH. Methylation of RUNX3 in various types of human 
cancers and premalignant stages of gastric carcinoma. Lab 
Invest 2004; 84: 479-484
10 Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L, Le X, Yao J, 
Wu TT, Huang S, Xie K. Loss of RUNX3 expression signifi-
cantly affects the clinical outcome of gastric cancer patients 
and its restoration causes drastic suppression of tumor 
growth and metastasis. Cancer Res 2005; 65: 4809-4816
11 Li WQ, Pan KF, Zhang Y, Dong CX, Zhang L, Ma JL, Zhou 
T, Li JY, You WC. RUNX3 methylation and expression as-
sociated with advanced precancerous gastric lesions in a 
Chinese population. Carcinogenesis 2011; 32: 406-410
12 Duell EJ, Travier N, Lujan-Barroso L, Clavel-Chapelon F, 
Boutron-Ruault MC, Morois S, Palli D, Krogh V, Panico S, 
Tumino R, Sacerdote C, Quirós JR, Sánchez-Cantalejo E, 
Navarro C, Gurrea AB, Dorronsoro M, Khaw KT, Allen NE, 
Key TJ, Bueno-de-Mesquita HB, Ros MM, Numans ME, 
Peeters PH, Trichopoulou A, Naska A, Dilis V, Teucher B, 
Kaaks R, Boeing H, Schütze M, Regner S, Lindkvist B, Jo-
hansson I, Hallmans G, Overvad K, Egeberg R, Tjønneland 
A, Lund E, Weiderpass E, Braaten T, Romieu I, Ferrari P, 
Jenab M, Stenling R, Aune D, Norat T, Riboli E, González 
CA. Alcohol consumption and gastric cancer risk in the Eu-
ropean Prospective Investigation into Cancer and Nutrition 
(EPIC) cohort. Am J Clin Nutr 2011; 94: 1266-1275
13 Mastoraki A, Danias N, Arkadopoulos N, Sakorafas G, 
Vasiliou P, Smyrniotis V. Prophylactic total gastrectomy for 
hereditary diffuse gastric cancer. Review of the literature. 
Surg Oncol 2011; 20: e223-e226
14 Lynch HT, Lynch JF. Hereditary diffuse gastric cancer: life-
saving total gastrectomy for CDH1 mutation carriers. J Med 
Genet 2010; 47: 433-435
15 Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka 
K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, 
Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T. 
High levels of aberrant DNA methylation in Helicobacter 
pylori-infected gastric mucosae and its possible association 
with gastric cancer risk. Clin Cancer Res 2006; 12: 989-995 
16 Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ich-
inose M, Sugiyama T, Ushijima T. DNA methylation of mi-
croRNA genes in gastric mucosae of gastric cancer patients: 
its possible involvement in the formation of epigenetic field 
defect. Int J Cancer 2009; 124: 2367-2374
17 Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, 
Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, Taka-
maru H, Niinuma T, Maruyama R, Yamamoto H, Tokino 
T, Imai K, Toyota M, Shinomura Y. Methylation-associated 
silencing of microRNA-34b/c in gastric cancer and its in-
volvement in an epigenetic field defect. Carcinogenesis 2010; 
31: 2066-2073
18 Loh JT, Torres VJ, Cover TL. Regulation of Helicobacter py-
lori cagA expression in response to salt. Cancer Res 2007; 67: 
4709-4715
19 Fox JG, Dangler CA, Taylor NS, King A, Koh TJ, Wang TC. 
High-salt diet induces gastric epithelial hyperplasia and 
parietal cell loss, and enhances Helicobacter pylori coloniza-
tion in C57BL/6 mice. Cancer Res 1999; 59: 4823-4828
20 Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: 
review of epidemiological evidence. Gastric Cancer 2007; 10: 
75-83
21 Tsukamoto T, Mizoshita T, Tatematsu M. Animal models of 
stomach carcinogenesis. Toxicol Pathol 2007; 35: 636-648 
22 Konturek PC, Konturek SJ, Brzozowski T. Helicobacter py-
lori infection in gastric cancerogenesis. J Physiol Pharmacol 
2009; 60: 3-21
23 Tanih NF, McMillan M, Naidoo N, Ndip LM, Weaver LT, 
Ndip RN. Prevalence of Helicobacter pylori vacA, cagA and 
iceA genotypes in South African patients with upper gastro-
intestinal diseases. Acta Trop 2010; 116: 68-73
24 Ramis IB, Fonseca TL, de Moraes EP, Fernandes MS, Men-
doza-Sassi R, Rodrigues O, Juliano CR, Scaini CJ, da Silva 
PE. Molecular Basis of pathogenicity in Helicobacter pylori 
clinical isolates. J Clin Microbiol 2010; 48: 3776-3778 
25 van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schnee-
berger P, de Boer W, Quint W. Clinical relevance of the 
cagA, vacA, and iceA status of Helicobacter pylori. Gastro-
enterology 1998; 115: 58-66 
26 Watada M, Shiota S, Matsunari O, Suzuki R, Murakami K, 
Fujioka T, Yamaoka Y. Association between Helicobacter 
pylori cagA-related genes and clinical outcomes in Colom-
bia and Japan. BMC Gastroenterol 2011; 11: 141
27 Wen S, Moss SF. Helicobacter pylori virulence factors in 
gastric carcinogenesis. Cancer Lett 2009; 282: 1-8
28 Kumar Pachathundikandi S, Brandt S, Madassery J, Backert 
S. Induction of TLR-2 and TLR-5 expression by Helicobacter 
pylori switches cagPAI-dependent signalling leading to the 
secretion of IL-8 and TNF-α. PLoS One 2011; 6: e19614 
29 Vincent CD, Buscher BA, Friedman JR, Williams LA, Bardi-
ll P, Vogel JP. Identification of non-dot/icm suppressors of 
the Legionella pneumophila DeltadotL lethality phenotype. 
J Bacteriol 2006; 188: 8231-8243
30 Hatakeyama M. Deregulation of SHP-2 tyrosine phospha-
tase by the Helicobacter pylori virulence factor CagA. Keio J 
Med 2002; 51 Suppl 2: 26-32
31 Hatakeyama M. Oncogenic mechanisms of the Helicobacter 
pylori CagA protein. Nat Rev Cancer 2004; 4: 688-694
32 Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci 
A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene 
A (CagA) subverts the apoptosis-stimulating protein of p53 
(ASPP2) tumor suppressor pathway of the host. Proc Natl 
Acad Sci USA 2011; 108: 9238-9243 
33 Rizzato C, Torres J, Plummer M, Muñoz N, Franceschi S, 
Camorlinga-Ponce M, Fuentes-Pananá EM, Canzian F, Kato 
I. Variations in Helicobacter pylori cytotoxin-associated 
genes and their influence in progression to gastric cancer: 
implications for prevention. PLoS One 2012; 7: e29605
34 Ushijima T, Hattori N. Molecular pathways: involvement of 
Helicobacter pylori-triggered inflammation in the formation 
of an epigenetic field defect, and its usefulness as cancer risk 
and exposure markers. Clin Cancer Res 2012; 18: 923-929 
35 Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funako-
shi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mu-
kaida N, Matsushima K. Molecular analysis of suppression 
of interleukin-8 production by rebamipide in Helicobacter 
pylori-stimulated gastric cancer cell lines. Dig Dis Sci 1998; 
133 September 10, 2012|Volume 3|Issue 9|WJCO|www.wjgnet.com
Giordano A et al . Gastric cancer prevention
43: 174S-180S
36 Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, 
Sumii K, Kajiyama G, Talley NJ. Helicobacter pylori infec-
tion and gastric neoplasia: correlations with histological 
gastritis and tumor histology. Am J Gastroenterol 1998; 93: 
1271-1276
37 El-Omar EM. The importance of interleukin 1beta in Helico-
bacter pylori associated disease. Gut 2001; 48: 743-747
38 Raghavan S, Quiding-Järbrink M. Immune modulation by 
regulatory T cells in Helicobacter pylori-associated diseases. 
Endocr Metab Immune Disord Drug Targets 2012; 12: 71-85 
39 Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-
Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. 
Current concepts in the management of Helicobacter pylori 
infection: the Maastricht III Consensus Report. Gut 2007; 56: 
772-781
40 Graham DY, Fischbach L. Helicobacter pylori treatment 
in the era of increasing antibiotic resistance. Gut 2010; 59: 
1143-1153
41 Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter 
pylori therapy from a meta-analytical perspective. Helico-
bacter 2007; 12 Suppl 2: 50-58
42 Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, 
Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low 
eradication rate of Helicobacter pylori with triple 7-14 days 
and quadriple therapy in Turkey. World J Gastroenterol 2004; 
10: 668-671 
43 Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. 
One-week triple therapy using omeprazole, amoxycillin and 
clarithromycin for the eradication of Helicobacter pylori 
in patients with non-ulcer dyspepsia: influence of dosage 
of omeprazole and clarithromycin. Aliment Pharmacol Ther 
1998; 12: 383-388
44 Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cam-
marota G. Third-line rescue therapy for Helicobacter pylori 
infection. World J Gastroenterol 2006; 12: 2313-2319
45 Mégraud F. H pylori antibiotic resistance: prevalence, im-
portance, and advances in testing. Gut 2004; 53: 1374-1384 
46 Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-
Helicobacter pylori therapy. World J Gastroenterol 2011; 17: 
3971-3975 
47 Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan 
C, Bernabucci V, Tampieri A, Morini S. Sequential therapy 
versus standard triple-drug therapy for Helicobacter pylori 
eradication: a randomized trial. Ann Intern Med 2007; 146: 
556-563
48 Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequen-
tial therapy or triple therapy for Helicobacter pylori infec-
tion: systematic review and meta-analysis of randomized 
controlled trials in adults and children. Am J Gastroenterol 
2009; 104: 3069-3079; quiz 1080
49 Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to 
extending the duration of Helicobacter pylori sequential 
therapy to 14 days? Helicobacter 2011; 16: 146-152
50 Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: 
four-drug, three-antibiotic, non-bismuth-containing “con-
comitant therapy” versus triple therapy for Helicobacter 
pylori eradication. Helicobacter 2009; 14: 109-118
51 Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, 
Wang SS, Chen A, Hung WC, Graham DY. Sequential and 
concomitant therapy with four drugs is equally effective for 
eradication of H pylori infection. Clin Gastroenterol Hepatol 
2010; 8: 36-41.e1
52 Shiotani A, Nishi R, Uedo N, Iishi H, Tsutsui H, Ishii M, 
Imamura H, Kamada T, Hata J, Haruma K. Helicobacter py-
lori eradication prevents extension of intestinalization even 
in the high-risk group for gastric cancer. Digestion 2010; 81: 
223-230
53 Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ce-
roni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter 
pylori eradication treatment reduce the risk for gastric can-
cer? Ann Intern Med 2009; 151: 121-128
54 Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early 
Helicobacter pylori eradication decreases risk of gastric 
cancer in patients with peptic ulcer disease. Gastroenterology 
2009; 137: 1641-1648.e1-2 
55 Mabe K, Takahashi M, Oizumi H, Tsukuma H, Shibata A, 
Fukase K, Matsuda T, Takeda H, Kawata S. Does Helico-
bacter pylori eradication therapy for peptic ulcer prevent 
gastric cancer? World J Gastroenterol 2009; 15: 4290-4297 
56 Kosunen TU, Pukkala E, Sarna S, Seppälä K, Aromaa A, 
Knekt P, Rautelin H. Gastric cancers in Finnish patients af-
ter cure of Helicobacter pylori infection: A cohort study. Int 
J Cancer 2011; 128: 433-439
57 Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama 
T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H, 
Kanda M, Hirahashi M, Matsumoto T. Long-term effect 
of Helicobacter pylori eradication on the development of 
metachronous gastric cancer after endoscopic resection of 
early gastric cancer. Gastrointest Endosc 2012; 75: 39-46
58 Yamamoto K, Kato M, Takahashi M, Haneda M, Shinada 
K, Nishida U, Yoshida T, Sonoda N, Ono S, Nakagawa M, 
Mori Y, Nakagawa S, Mabe K, Shimizu Y, Moriya J, Kubota 
K, Matsuno Y, Shimoda T, Watanabe H, Asaka M. Clinico-
pathological analysis of early-stage gastric cancers detected 
after successful eradication of Helicobacter pylori. Helico-
bacter 2011; 16: 210-216
59 Matsuo T, Ito M, Tatsugami M, Boda T, Takata S, Tanaka S, 
Chayama K. Gastric cancer development after Helicobacter 
pylori eradication therapy: a new form of gastric neoplasia. 
Digestion 2012; 85: 61-67
60 Schistosomes, liver flukes and Helicobacter pylori. IARC 
Working Group on the Evaluation of Carcinogenic Risks to 
Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog 
Risks Hum 1994; 61: 1-241 
61 Shin SH, Park SY, Ko JS, Kim N, Kang GH. Aberrant CpG 
island hypermethylation in pediatric gastric mucosa in as-
sociation with Helicobacter pylori infection. Arch Pathol Lab 
Med 2011; 135: 759-765
62 Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa 
K, Ushijima T. The presence of a methylation fingerprint of 
Helicobacter pylori infection in human gastric mucosae. Int 
J Cancer 2009; 124: 905-910
63 Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus 
I, Stephenson KK, Talalay P, Lozniewski A. Sulforaphane 
inhibits extracellular, intracellular, and antibiotic-resistant 
strains of Helicobacter pylori and prevents benzo[a]pyrene-
induced stomach tumors. Proc Natl Acad Sci USA 2002; 99: 
7610-7615 
64 Oijen AH, Verhulst ML, Roelofs HM, Peters WH, de Boer 
WA, Jansen JB. Eradication of Helicobacter pylori restores 
glutathione S-transferase activity and glutathione levels in 
antral mucosa. Jpn J Cancer Res 2001; 92: 1329-1334
65 Tripathi S, Ghoshal U, Mittal B, Chourasia D, Kumar S, 
Ghoshal UC. Association between gastric mucosal glutathi-
one-S-transferase activity, glutathione-S-transferase gene 
polymorphisms and Helicobacter pylori infection in gastric 
cancer. Indian J Gastroenterol 2011; 30: 257-263 
66 Yanaka A, Fahey JW, Fukumoto A, Nakayama M, Inoue S, 
Zhang S, Tauchi M, Suzuki H, Hyodo I, Yamamoto M. Di-
etary sulforaphane-rich broccoli sprouts reduce colonization 
and attenuate gastritis in Helicobacter pylori-infected mice 
and humans. Cancer Prev Res (Phila) 2009; 2: 353-360
67 Blaser MJ. Who are we? Indigenous microbes and the ecol-
ogy of human diseases. EMBO Rep 2006; 7: 956-960 
68 Wewer V, Kalach N. Helicobacter pylori infection in pediat-
rics. Helicobacter 2003; 8 Suppl 1: 61-67
69 Bakka AS, Salih BA. Prevalence of Helicobacter pylori in-
fection in asymptomatic subjects in Libya. Diagn Microbiol 
Infect Dis 2002; 43: 265-268
134 September 10, 2012|Volume 3|Issue 9|WJCO|www.wjgnet.com
Giordano A et al . Gastric cancer prevention
70 Vitale G, Barbaro F, Ianiro G, Cesario V, Gasbarrini G, 
Franceschi F, Gasbarrini A. Nutritional aspects of Helico-
bacter pylori infection. Minerva Gastroenterol Dietol 2011; 57: 
369-377
71 Akcam M. Helicobacter pylori and micronutrients. Indian 
Pediatr 2010; 47: 119-126
72 Thomas JE, Dale A, Bunn JE, Harding M, Coward WA, Cole 
TJ, Weaver LT. Early Helicobacter pylori colonisation: the 
association with growth faltering in The Gambia. Arch Dis 
Child 2004; 89: 1149-1154
73 Windle HJ, Kelleher D, Crabtree JE. Childhood Helicobacter 
pylori infection and growth impairment in developing 
countries: a vicious cycle? Pediatrics 2007; 119: e754-e759 
74 Gulcan M, Ozen A, Karatepe HO, Gulcu D, Vitrinel A. 
Impact of H. pylori on growth: is the infection or mucosal 
disease related to growth impairment? Dig Dis Sci 2010; 55: 
2878-2886
75 Bourke B. Will treatment of Helicobacter pylori infection in 
childhood alter the risk of developing gastric cancer? Can J 
Gastroenterol 2005; 19: 409-411 
76 Malaty HM. Helicobacter pylori infection and eradication 
in paediatric patients. Paediatr Drugs 2000; 2: 357-365
77 Yang YJ, Sheu BS. Sequential therapy in childhood Helico-
bacter pylori eradication: emphasis on drug compliance. J 
Pediatr 2011; 159: 700; author reply 700-701 
78 Yang YJ, Yang JC, Jeng YM, Chang MH, Ni YH. Prevalence 
and rapid identification of clarithromycin-resistant Helico-
bacter pylori isolates in children. Pediatr Infect Dis J 2001; 20: 
662-666
79 Appelman HD, Umar A, Orlando RC, Sontag SJ, Nandur-
kar S, El-Zimaity H, Lanas A, Parise P, Lambert R, Shields 
HM. Barrett’s esophagus: natural history. Ann N Y Acad Sci 
2011; 1232: 292-308
80 Tytgat GN. Recent developments in gastroesophageal re-
flux disease and Barrett’s esophagus: ANNO 2012. J Dig Dis 
2012; 13: 291-295
81 Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margan-
tinis G. Relationship between Helicobacter pylori infection 
and esophageal neoplasia: a meta-analysis. Clin Gastroenterol 
Hepatol 2007; 5: 1413-1417
82 Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection 
and Barrett’s esophagus: a systematic review and meta-
analysis. Am J Gastroenterol 2009; 104: 492-500; quiz 491, 501 
83 Jakszyn P, Agudo A, Lujan-Barroso L, Bueno-de-Mesquita 
HB, Jenab M, Navarro C, Palli D, Boeing H, Manjer J, Nu-
mans ME, Igali L, Boutron-Ruault MC, Clavel-Chapelon F, 
Morois S, Grioni S, Panico c, Tumino R, Sacerdote C, Quirós 
JR, Molina-Montes E, Huerta Castaño JM, Barricarte A, 
Amiano P, Khaw KT, Wareham N, Allen NE, Key TJ, Jeurn-
ink SM, Peeters PH, Bamia C, Valanou E, Trichopoulou A, 
Kaaks R, Lukanova A, Bergmann MM, Lindkvist B, Stenling 
R, Johansson I, Dahm CC, Overvad K, Olsen A, Tjonneland 
A, Skeie G, Broderstad AR, Lund E, Michaud DS, Mouw 
T, Riboli E, González CA. Dietary intake of heme iron and 
risk of gastric cancer in the European prospective investiga-
tion into cancer and nutrition study. Int J Cancer 2012; 130: 
2654-2663
84 Babaei M, Pourfarzi F, Yazdanbod A, Chiniforush MM, 
Derakhshan MH, Mousavi SM, Samadi F, Rahimi G. Gastric 
cancer in Ardabil, Iran--a review and update on cancer reg-
istry data. Asian Pac J Cancer Prev 2010; 11: 595-599
85 González CA, Jakszyn P, Pera G, Agudo A, Bingham S, Pal-
li D, Ferrari P, Boeing H, del Giudice G, Plebani M, Carneiro 
F, Nesi G, Berrino F, Sacerdote C, Tumino R, Panico S, Ber-
glund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dor-
ronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key 
TJ, Day NE, Linseisen J, Nagel G, Bergmann MM, Overvad 
K, Jensen MK, Tjonneland A, Olsen A, Bueno-de-Mesquita 
HB, Ocke M, Peeters PH, Numans ME, Clavel-Chapelon F, 
Boutron-Ruault MC, Trichopoulou A, Psaltopoulou T, Rou-
kos D, Lund E, Hemon B, Kaaks R, Norat T, Riboli E. Meat 
intake and risk of stomach and esophageal adenocarcinoma 
within the European Prospective Investigation Into Cancer 
and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 345-354 
86 Strumylaite L, Zickute J, Dudzevicius J, Dregval L. Salt-
preserved foods and risk of gastric cancer. Medicina (Kaunas) 
2006; 42: 164-170
87 Shikata K, Kiyohara Y, Kubo M, Yonemoto K, Ninomiya T, 
Shirota T, Tanizaki Y, Doi Y, Tanaka K, Oishi Y, Matsumoto 
T, Iida M. A prospective study of dietary salt intake and 
gastric cancer incidence in a defined Japanese population: 
the Hisayama study. Int J Cancer 2006; 119: 196-201
88 Pakseresht M, Forman D, Malekzadeh R, Yazdanbod A, 
West RM, Greenwood DC, Crabtree JE, Cade JE. Dietary 
habits and gastric cancer risk in north-west Iran. Cancer 
Causes Control 2011; 22: 725-736
89 Sumathi B, Ramalingam S, Navaneethan U, Jayanthi V. 
Risk factors for gastric cancer in South India. Singapore Med 
J 2009; 50: 147-151
90 Ramón JM, Serra L, Cerdó C, Oromí J. Dietary factors and 
gastric cancer risk. A case-control study in Spain. Cancer 
1993; 71: 1731-1735
91 WHO Disease and injury country estimates. World Health 
Organization. 2009.
92 Tsugane S, de Souza JM, Costa ML, Mirra AP, Gotlieb SL, 
Laurenti R, Watanabe S. Cancer incidence rates among Japa-
nese immigrants in the city of São Paulo, Brazil, 1969-78. 
Cancer Causes Control 1990; 1: 189-193
93 Tsugane S, Gey F, Ichinowatari Y, Miyajima Y, Ishibashi T, 
Matsushima S, Hirota Y, Inami T, Yamaguchi M, Karita K, 
Kabuto M, Takashima Y, Todoriki H, Tsuda M, Akabane M, 
Furuichi Y, Hamada G, Watanabe S. Cross-sectional Epide-
miologic Study for Assessing Cancer Risks at the Population 
Level I. Study Design and Participation Rate. J Epidemiol 
1992; 2: 75-81
94 Watanabe H, Hirayama T. [Stomach cancer mortality and 
life styles in Niigata Prefecture]. Gan No Rinsho 1990; Spec 
No: 285-291
95 Peek RM, Wirth HP, Moss SF, Yang M, Abdalla AM, Tham 
KT, Zhang T, Tang LH, Modlin IM, Blaser MJ. Helicobacter 
pylori alters gastric epithelial cell cycle events and gastrin 
secretion in Mongolian gerbils. Gastroenterology 2000; 118: 
48-59
96 Kato S, Tsukamoto T, Mizoshita T, Tanaka H, Kumagai 
T, Ota H, Katsuyama T, Asaka M, Tatematsu M. High salt 
diets dose-dependently promote gastric chemical carcino-
genesis in Helicobacter pylori-infected Mongolian gerbils 
associated with a shift in mucin production from glandular 
to surface mucous cells. Int J Cancer 2006; 119: 1558-1566 
97 Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Ray-
chowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox 
JG. Synergistic interaction between hypergastrinemia and 
Helicobacter infection in a mouse model of gastric cancer. 
Gastroenterology 2000; 118: 36-47
98 Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scot-
ti L, Islami F, Corrao G, La Vecchia C, Boffetta P. A meta-
analysis on alcohol drinking and gastric cancer risk. Ann 
Oncol 2012; 23: 28-36
99 Kim J, Cho YA, Choi IJ, Lee YS, Kim SY, Shin A, Cho SJ, 
Kook MC, Nam JH, Ryu KW, Lee JH, Kim YW. Effects of in-
terleukin-10 polymorphisms, Helicobacter pylori infection, 
and smoking on the risk of noncardia gastric cancer. PLoS 
One 2012; 7: e29643
100 Shin A, Kim J, Park S. Gastric cancer epidemiology in Ko-
rea. J Gastric Cancer 2011; 11: 135-140
101 Gao Y, Hu N, Han XY, Ding T, Giffen C, Goldstein AM, 
Taylor PR. Risk factors for esophageal and gastric cancers in 
Shanxi Province, China: a case-control study. Cancer Epide-
miol 2011; 35: e91-e99
102 Shin CM, Kim N, Cho SI, Kim JS, Jung HC, Song IS. As-
135 September 10, 2012|Volume 3|Issue 9|WJCO|www.wjgnet.com
Giordano A et al . Gastric cancer prevention
sociation between alcohol intake and risk for gastric cancer 
with regard to ALDH2 genotype in the Korean population. 
Int J Epidemiol 2011; 40: 1047-1055
103 Velmurugan B, Bhuvaneswari V, Abraham SK, Nagini S. 
Protective effect of tomato against N-methyl-N’-nitro-N-
nitrosoguanidine-induced in vivo clastogenicity and oxida-
tive stress. Nutrition 2004; 20: 812-816
104 Bae JM, Lee EJ, Guyatt G. Citrus fruit intake and stomach 
cancer risk: a quantitative systematic review. Gastric Cancer 
2008; 11: 23-32
105 Hajimahmoodi M, Shams-Ardakani M, Saniee P, Siavoshi 
F, Mehrabani M, Hosseinzadeh H, Foroumadi P, Safavi 
M, Khanavi M, Akbarzadeh T, Shafiee A, Foroumadi A. In 
vitro antibacterial activity of some Iranian medicinal plant 
extracts against Helicobacter pylori. Nat Prod Res 2011; 25: 
1059-1066
106 Velmurugan B, Mani A, Nagini S. Combination of S-all-
ylcysteine and lycopene induces apoptosis by modulating 
Bcl-2, Bax, Bim and caspases during experimental gastric 
carcinogenesis. Eur J Cancer Prev 2005; 14: 387-393
107 Marnett LJ. Lipid peroxidation-DNA damage by malondi-
aldehyde. Mutat Res 1999; 424: 83-95
108 Stähelin HB, Rösel F, Buess E, Brubacher G. Cancer, vi-
tamins, and plasma lipids: prospective Basel study. J Natl 
Cancer Inst 1984; 73: 1463-1468
109 Xu GP, Song PJ, Reed PI. Effects of fruit juices, processed 
vegetable juice, orange peel and green tea on endogenous 
formation of N-nitrosoproline in subjects from a high-risk 
area for gastric cancer in Moping County, China. Eur J Can-
cer Prev 1993; 2: 327-335
110 La Vecchia C, Negri E, Decarli A, D’Avanzo B, Franceschi S. 
A case-control study of diet and gastric cancer in northern 
Italy. Int J Cancer 1987; 40: 484-489
111 Steevens J, Schouten LJ, Goldbohm RA, van den Brandt 
PA. Vegetables and fruits consumption and risk of esopha-
geal and gastric cancer subtypes in the Netherlands Cohort 
Study. Int J Cancer 2011; 129: 2681-2693
112 Lee DH, Park KI, Park HS, Kang SR, Nagappan A, Kim JA, 
Kim EH, Lee WS, Hah YS, Chung HJ, An SJ, Kim GS. Flavo-
noids Isolated from Korea Citrus aurantium L. Induce G2/
M Phase Arrest and Apoptosis in Human Gastric Cancer 
AGS Cells. Evid Based Complement Alternat Med 2012; 2012: 
515901
113 Sekiguchi H, Washida K, Murakami A. Suppressive Effects 
of Selected Food Phytochemicals on CD74 Expression in 
NCI-N87 Gastric Carcinoma Cells. J Clin Biochem Nutr 2008; 
43: 109-117
114 Sekiguchi H, Irie K, Murakami A. Suppression of CD74 
expression and Helicobacter pylori adhesion by auraptene 
targeting serum starvation-activated ERK1/2 in NCI-N87 
gastric carcinoma cells. Biosci Biotechnol Biochem 2010; 74: 
1018-1024
115 Kim MJ, Park HJ, Hong MS, Park HJ, Kim MS, Leem KH, 
Kim JB, Kim YJ, Kim HK. Citrus Reticulata blanco induces 
apoptosis in human gastric cancer cells SNU-668. Nutr Can-
cer 2005; 51: 78-82
116 Sato K, Kawakami N, Ohtsu T, Tsutsumi A, Miyazaki S, 
Masumoto T, Horie S, Haratani T, Kobayashi F, Araki S. 
Broccoli consumption and chronic atrophic gastritis among 
Japanese males: an epidemiological investigation. Acta Med 
Okayama 2004; 58: 127-133 
117 Freedman ND, Subar AF, Hollenbeck AR, Leitzmann MF, 
Schatzkin A, Abnet CC. Fruit and vegetable intake and gas-
tric cancer risk in a large United States prospective cohort 
study. Cancer Causes Control 2008; 19: 459-467
118 Key TJ. Fruit and vegetables and cancer risk. Br J Cancer 
2011; 104: 6-11
119 Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosa-
to Y, Takeichi M, Abe O. Cadherin cell-adhesion molecules 
in human epithelial tissues and carcinomas. Cancer Res 1989; 
49: 2128-2133
120 Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello 
F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, 
MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C. 
Identification of germ-line E-cadherin mutations in gastric 
cancer families of European origin. Cancer Res 1998; 58: 
4086-4089
121 Yoon KA, Ku JL, Yang HK, Kim WH, Park SY, Park JG. 
Germline mutations of E-cadherin gene in Korean familial 
gastric cancer patients. J Hum Genet 1999; 44: 177-180 
122 Yamada H, Shinmura K, Ito H, Kasami M, Sasaki N, Shima 
H, Ikeda M, Tao H, Goto M, Ozawa T, Tsuneyoshi T, Tanio-
ka F, Sugimura H. Germline alterations in the CDH1 gene in 
familial gastric cancer in the Japanese population. Cancer Sci 
2011; 102: 1782-1788
123 Corso G, Marrelli D, Pascale V, Vindigni C, Roviello F. Fre-
quency of CDH1 germline mutations in gastric carcinoma 
coming from high- and low-risk areas: metanalysis and sys-
tematic review of the literature. BMC Cancer 2012; 12: 8 
124 Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, 
Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van 
Krieken JH, Dwerryhouse S, Caldas C. Hereditary diffuse 
gastric cancer: updated consensus guidelines for clinical 
management and directions for future research. J Med Genet 
2010; 47: 436-444
125 Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric 
cancer: implications of genetic testing for screening and pro-
phylactic surgery. Cancer 2008; 113: 1850-1856
126 Chen Y, Kingham K, Ford JM, Rosing J, Van Dam J, Jef-
frey RB, Longacre TA, Chun N, Kurian A, Norton JA. A 
prospective study of total gastrectomy for CDH1-positive 
hereditary diffuse gastric cancer. Ann Surg Oncol 2011; 18: 
2594-2598
127 Terdiman JP. Hereditary diffuse gastric cancer: surveillance 
endoscopy is not enough to save lives. Gastroenterology 2007; 
133: 1730-1732; discussion 1732-1733 
128 Mori J, Vranac T, Smrekar B, Cernilec M, Serbec VČ, Horvat 
S, Ihan A, Benčina M, Jerala R. Chimeric flagellin as the self-
adjuvanting antigen for the activation of immune response 
against Helicobacter pylori. Vaccine 2012; 30: 5856-5863 
129 Lim H, Cho G, Kim S. Evaluation of nutrient intake and diet 
quality of gastric cancer patients in Korea. Nutr Res Pract 
2012; 6: 213-220
130 Nagini S. Carcinoma of the stomach: A review of epidemi-
ology, pathogenesis, molecular genetics and chemopreven-
tion. World J Gastrointest Oncol 2012; 4: 156-169
S- Editor  Jiang L    L- Editor  A    E- Editor  Li JY
136 September 10, 2012|Volume 3|Issue 9|WJCO|www.wjgnet.com
Giordano A et al . Gastric cancer prevention
